采用Cell-SELEX技术的核酸适配体在肿瘤靶向治疗的研究进展  

Research Progress of Aptamers Using Cell-SELEX Technology in Cancer Targeted Treatment

作　　者：成志云[1] 陈佳怡 白如玉[1] 杨会勇[1] MOHSAN Ullah 刁勇[1] CHENG Zhiyun;CHEN Jiayi;BAI Ruyu;YANG Huiyong;MOHSAN Ullah;DIAO Yong(School of Medicine,Huaqiao University,Quanzhou 362021,China)

机构地区：[1]华侨大学医学院,福建泉州362021

出　　处：《华侨大学学报（自然科学版）》2024年第4期439-444,共6页Journal of Huaqiao University(Natural Science)

基　　金：国家自然科学基金资助项目(20141ZA003);福建省泉州市高层次人才创新项目(20221ZC061)。

摘　　要：阐述细胞-配体指数富集系统进化(Cell-SELEX)技术特点,以及通过该技术筛选得到的核酸适配体在肿瘤靶向治疗中的应用进展和挑战,通过查阅近年的相关文献,综述核酸适配体作为药物及药物载体在肿瘤靶向治疗中的应用研究进展。结果表明:基于Cell-SELEX技术筛选得到的核酸适配体在肿瘤靶向治疗中的疗效显著,可开发成为肿瘤靶向治疗的潜力药物及良好的药物载体。The characteristics of cell-systematic evolution of ligands by exponential enrichment(Cell-SELEX)technology as well as the application progress and challenges of screened aptamers in cancer-targeted treatment through this technology were expounded.And the research progress about cancer-targeted treatment applications of aptamers as drugs or drug carriers were reviewed by consulting relevant literature in recent years.The results show that the aptamers screened based on Cell-SELEX technology have significant therapeutic effects and can be developed as potential drugs and good drug carriers in cancer-targeted treatment.

关 键 词：核酸适配体 细胞-配体指数富集系统进化(Cell-SELEX)技术 肿瘤 靶向治疗 

分 类 号：R944[医药卫生—药剂学]